vTv Therapeutics Inc
vtvtherapeutics.comWhat Do They Do?
Develops oral drug candidates for diabetes and other chronic diseases, led by cadisegliatin, an investigational therapy intended to be taken alongside insulin.
10-K for FY2025, filed Mar 10, 2026
Who Are Their Customers?
Pharmaceutical partners license drug candidates and collaborate on development; the company also works with academic partners on other pipeline candidates.
10-K for FY2025, filed Mar 10, 2026In addition to our clinical development program for cadisegliatin, we continue to advance the research and development of our other…View ↗
Seeking additional strategic collaborations and additional funding to support the continued development and commercialization of our…View ↗
We also continue to seek strategic collaborations with other pharmaceutical companies, such as our partnerships with Cantex and Newsoara…View ↗
Most of our collaboration revenue for the years ended December 31, 2025, 2024 and 2023 is related to our licenses of certain compounds in…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$13.1MView ↗
- ▲ +116% (Loss)
- vs −$6M in Q2 FY2025
-
Aug 6, 2026
Plans to start a Phase 2a trial using hybrid closed-loop insulin systems
The trial is expected to begin before year end 2026 and will study cadisegliatin in people with type 1 diabetes.
Sources
8-K, filed Aug 6, 2026
Cadisegliatin Phase 2a hybrid closed-loop trial (Hybrid CATT1) in T1D to initiate before year end 2026View ↗
Broader disease focus
The older report described the company as focused on oral treatments for diabetes while also naming metabolic and inflammatory diseases. The latest report frames its drug candidates as intended for diabetes and other chronic diseases.
10-K for FY2022, filed Mar 6, 2023 10-K for FY2025, filed Mar 10, 2026We are a clinical stage biopharmaceutical company focused on the development of orally administered treatments for diabetes. We are focused…View ↗
We are a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people…View ↗
Fewer partnered programs emphasized
The older report described five partnered programs across several drug types. The latest report instead highlights cadisegliatin and says it continues research on other pipeline candidates through academic collaborations and license agreements.
10-K for FY2022, filed Mar 6, 2023 10-K for FY2025, filed Mar 10, 2026In addition to our internal development programs, we are continuing to further the development of five partnered programs: a small molecule…View ↗
In addition to our clinical development program for cadisegliatin, we continue to advance the research and development of our other…View ↗
Who Do They Compete With?
Competes with Zucara Therapeutics, Diasome Pharmaceuticals, Lexicon Pharmaceuticals, Adocia, Sanofi, Vertex Pharmaceuticals, Eli Lilly, and TIXiMED
10-K for FY2025, filed Mar 10, 2026Adjunctive non-insulin pharmacotherapies and hypoglycemia-focused approaches. Multiple companies are developing agents intended to improve…View ↗
Loading...
